Applicability of FDA Labeling for Dapagliflozin to Patients With HFrEF in US Clinical Practice
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Cardiology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With The Guidelines–Heart Failure (GWTG-HF) Registry
JAMA Cardiol 2020 Nov 13;[EPub Ahead of Print], M Vaduganathan, SJ Greene, S Zhang, M Grau-Sepulveda, AD DeVore, J Butler, PA Heidenreich, JC Huang, MM Kittleson, KE Joynt Maddox, JJ McDermott, AT Owens, PN Peterson, SD Solomon, O Vardeny, CW Yancy, GC FonarowFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.